NCT05221164

162 mg of Aspirin for Prevention of Preeclampsia

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Methodist Medical Center of Illinois · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Accepted

Summary

This is a study to assess if 162 mg of aspirin will decrease rates of preeclampsia in pregnant patients compared to 81 mg of aspirin.

Detailed description

After screening to meet inclusion criteria, pregnant patients at the Family Medicine Clinic will be asked to take 162 mg aspirin daily for 6 months, starting at about 12 weeks gestation and continued until the end of pregnancy. They will be monitored every 4 weeks until week 28, then every 2 weeks until week 36, and then weekly from week 36 on. Participants will be screened at these visits for medication compliance (taking, missed doses, side effects, etc). Patients will be subject to lab work as is routinely indicated for preeclampsia. At the end of the study period, accumulated study data will be compared with historical data from the Family Medicine Clinic on rates of preeclampsia and outcomes in patients taking 81 mg for preeclampsia prevention.

Conditions

• Preeclampsia

Interventions

Type	Name	Description
DRUG	Aspirin 162 mg	Daily aspirin 162 mg during pregnancy to prevent preeclampsia

Timeline

• Start date: 2021-07-06
• Primary completion: 2022-06-09
• Completion: 2022-06-09
• First posted: 2022-02-02
• Last updated: 2022-02-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study